Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

2723 - Prognostic impact of RNA expression profile (EP) in the phase III DECISION trial for patients with advanced radioactive-iodine refractory differentiated thyroid cancer (DTC).

Date

11 Sep 2017

Session

Endocrine and neuroendocrine tumours

Presenters

Ignacio Matos

Citation

Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368

Authors

I. Matos1, F. Mancuso2, C. Iglesias3, P. Nuciforo4, C. Zafón5, H.G. Palmer6, Z. Ogbah2, L. Muños2, G. Villacampa Javierre7, C. Peña8, M.S. Brose9, M. Schlumberger10, A. Vivancos2, J. Capdevila1

Author affiliations

  • 1 Oncology, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 2 Cancer Genomics Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 3 Pathology, Valle d´Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Molecular Oncology Group, Vall d´Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 5 Endocrinology, Valle d´Hebron University Hospital, 08035 - Barcelona/ES
  • 6 Stem Cells And Cancer Group, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
  • 7 Oncology Data Science (odyssey) Group, Vall d'Hebron Institute of Oncology, 08035 - Barcelona/ES
  • 8 Biomarker Strategy, Bayer HealthCare Pharmaceuticals, 07981 - Whippany/US
  • 9 Medical Oncology, University of Pennsylvania- CRB, 19104 - Philadelphia/US
  • 10 Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
More

Resources

Abstract 2723

Background

Sorafenib has demonstrated a significant impact in progression free survival (PFS) in patients with advanced DTC in the DECISION trial. BRAF and RAS mutation status (MS) have not shown prognostic significance on PFS and overall survival (OS) in multivariate model. The aim of this study was to correlate different RNA expression profiles with PFS and OS in a multivariate model.

Methods

We previously identified 3 expression profiles, BRAF, RAS and non-BRAF/RAS-like based on RNA-seq analysis (77 million paired-end reads for each sample on HiSeq2000) of 125 tumour samples of patients included in the DECISION trial. RNAseq reads were mapped against the human reference genome (GRCh38) with STAR (v2.5.1b) using ENCODE parameter. We used multivariate Cox proportional models to study the association between clinical variables (sex, age, thyroid cancer histology, Eastern Cooperative Oncology Group performance status), arm of treatment and biomarkers (EP and MS) with PFS and OS.

Results

The clinical variables in each expression profiles are shown in Table. Multivariable analysis indicated that only sorafenib treatment (HR: 0.39, 95% CI 0.23-0.66, p 

Conclusions

RNA-seq analysis identifies 3 different expression profiles in DTC: BRAF-like, RAS-like and non-BRAF/RAS-like. BRAF-like EP includes almost all BRAF mutant tumors but also a 45% of tumors with no mutation in BRAF gene. In the multivariate analysis, BRAF-like EP has shown a better prognostic factor for PFS in DTC and for OS in PTC.

Clinical trial identification

Legal entity responsible for the study

Vall d’Hebron Institute of Oncology

Funding

Bayer HealthCare Pharmaceuticals, Inc.

Disclosure

C. Peña: Bayer employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.